tbuckley/cabot-search huggingface dataset:
Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays
Authors: Antonin Bal, Mary-Anne Trabaud, Jean-Baptiste Fassier, Muriel Rabilloud, Kahina Saker, Carole Langlois-Jacques, Nicolas Guibert, Adèle Paul, Dulce Alfaiate, Amélie Massardier-Pilonchery, Virginie Pitiot, Florence Morfin-Sherpa, Bruno Lina, Bruno Pozzetto, Sophie Trouillet-Assant, Adnot Jérôme, Alfaiate Dulce, Bal Antonin, Bergeret Alain, Boibieux André, Bonnet Florent, Bourgeois Gaëlle, Brunel-Dalmas Florence, Caire Eurydice, Charbotel Barbara, Chiarello Pierre, Cotte Laurent, Constance d'Aubarede, Durupt François, Escuret Vanessa, Fascia Pascal, Fassier Jean-Baptiste, Fontaine Juliette, Gaillot-Durand Lucie, Gaymard Alexandre, Gillet Myriam, Godinot Matthieu, Gueyffier François, Guibert Nicolas, Josset Laurence, Lahousse Matthieu, Lina Bruno, Lozano Hélène, Makhloufi Djamila, Massardier-Pilonchéry Amélie, Milon Marie-Paule, Moll Frédéric, Morfin Florence, Narbey David, Nazare Julie-Anne, Oria Fatima, Paul Adèle, Perry Marielle, Pitiot Virginie, Prudent Mélanie, Rabilloud Muriel, Samperiz Audrey, Schlienger Isabelle, Simon Chantal, Trabaud Mary-Anne, Trouillet-Assant Sophie, Valette Martine
Journal: Clinical Microbiology and Infection (2021)
Prosthetic Valve Thrombosis: When and How Should We Lyse?⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.
Authors: Sreekanth Vemulapalli, Manesh R. Patel
Journal: JACC. Cardiovascular imaging (2013)
Abstract 10377: Coronary Artery Calcium Testing to Guide Statin Allocation According to ASCVD Risk-enhancing Factors: Results From The Multi-ethnic Study of Atherosclerosis (MESA)
Authors: Ramzi Dudum, Jaideep Patel, John W McEvoy, Roger S Blumenthal, Salim S Virani, Michael D Miedema, Steven Shea, Joseph Yeboah, Philip Greenland, Antonio Abbate, William G Hundley, Khurram Nasir, Amy Karger, Michael Y Tsai, Michael J Blaha, Mahmoud S Al Rifai
Journal: Circulation (2019)

Introduction: The 2018 AHA/ACC Multi-Society Cholesterol Guideline suggests risk-enhancing factors (REF) and coronary artery calcium (CAC) scoring for further risk stratification of atherosclerotic...
Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study
Authors: Martijne H C Duvekot, Esmee Venema, Anouk D Rozeman, Walid Moudrous, Frédérique H Vermeij, Marileen Biekart, Hester F Lingsma, Lisette Maasland, Annemarie D Wijnhoud, Laus J M M Mulder, Kees C L Alblas, Roeland P J van Eijkelenburg, Bianca I Buijck, Jeannette Bakker, Aarnout S Plaisier, Jan-Hein Hensen, Geert J Lycklama à Nijeholt, Pieter Jan van Doormaal, Adriaan C G M van Es, Aad van der Lugt, Henk Kerkhoff, Diederik W J Dippel, Bob Roozenbeek, Diederik W.J. Dippel, Bob Roozenbeek, Henk Kerkhoff, Hester F. Lingsma, Aad van der Lugt, Adriaan C.G.M van Es, Anouk D. Rozeman, Walid Moudrous, Frédérique H. Vermeij, Esmee Venema, Martijne H.C. Duvekot, Kees C.L. Alblas, Laus J.M.M. Mulder, Annemarie D. Wijnhoud, Lisette Maasland, Roeland P.J. van Eijkelenburg, Marileen Biekart, Merel L. Willeboer, Bianca Buijck, Pieter Jan van Doormaal, Jeannette Bakker, Jan-Hein Hensen, Aarnout Plaisier, Geert Lycklama à Nijeholt, Amber Hoek, Erick Oskam, Mandy M.A. van der Zon, Egon D. Zwets, Jan Willem Kuiper, Bruno J.M. van Moll, Mirjam Woudenberg, Arnoud M. de Leeuw, Anja Noordam-Reijm, Timo Bevelander, Vicky Chalos, Eveline J.A. Wiegers, Lennard Wolff, Dennis C. van Kalkeren, Jochem van den Biggelaar
Journal: The Lancet Neurology (2021)
Acute Brain Stroke Evolution Detected by 18F-FDG PET/CT and MRI Justifies the Discordance of Lesions in a Patient With Lymphoproliferative Syndrome
Authors: Paula Fernández-Rodríguez, Daniella Tamayo Carabaño, Rosa Fernández López, Pilar Piñero González de la Peña, Isabel Borrego Dorado
Journal: Clinical Nuclear Medicine (2021)

A 50-year-old man with angioimmunoblastic T-cell lymphoma in complete response to treatment presented new hypermetabolic brain lesions on 18F-FDG PET/CT suggestive of malignancy. These findings were correlated by MRI that showed cortical-subcortical peripheral lesions typical of acute ischemic infarction. A restaging 18F-FDG PET/CT showed that hypermetabolic lesions were replaced by ametabolic areas, supporting chronic infarction. Early ischemia presents transitory FDG increase. Brain lymphomas are highly FDG avid and difficult to differentiate from acute cerebral infarction. In view of the discordance of abnormal areas of intracranial uptake on PET FDG, MRI confirmation is required to avoid misinterpretation.
Impact of mass testing during an epidemic rebound of SARS-CoV-2: a modelling study using the example of France
Authors: Paolo Bosetti, Cécile Tran Kiem, Yazdan Yazdanpanah, Arnaud Fontanet, Bruno Lina, Vittoria Colizza, Simon Cauchemez
Journal: Eurosurveillance (2021)

We used a mathematical model to evaluate the impact of mass testing in the control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Under optimistic assumptions, one round of mass testing may reduce daily infections by up to 20–30%. Consequently, very frequent testing would be required to control a quickly growing epidemic if other control measures were to be relaxed. Mass testing is most relevant when epidemic growth remains limited through a combination of interventions.
The Rapid Rise in Cutaneous Melanoma Diagnoses
Authors: H. Gilbert Welch, Benjamin L. Mazer, Adewole S. Adamson
Journal: New England Journal of Medicine (2021)

The incidence of melanoma of the skin is 6 times as high as it was 40 years ago; mortality has stayed low. UV light exposure is the strongest environmental risk factor, but its magnitude gives a relative risk of about 2. The most likely factors influencing the increase are changing thresholds to biopsy pigmented lesions and to label the morphologic change as melanoma.
Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses
Authors: Uri Landes, Janarthanan Sathananthan, Guy Witberg, Ole De Backer, Lars Sondergaard, Mohamed Abdel-Wahab, David Holzhey, Won-Keun Kim, Christian Hamm, Nicola Buzzatti, Matteo Montorfano, Sebastian Ludwig, Lenard Conradi, Moritz Seiffert, Mayra Guerrero, Abdallah El Sabbagh, Josep Rodés-Cabau, Leonardo Guimaraes, Pablo Codner, Taishi Okuno, Thomas Pilgrim, Claudia Fiorina, Antonio Colombo, Antonio Mangieri, Helene Eltchaninoff, Luis Nombela-Franco, Maarten P.H. Van Wiechen, Nicolas M. Van Mieghem, Didier Tchétché, Wolfgang H. Schoels, Matthias Kullmer, Corrado Tamburino, Jan-Malte Sinning, Baravan Al-Kassou, Gidon Y. Perlman, Haim Danenberg, Alfonso Ielasi, Chiara Fraccaro, Giuseppe Tarantini, Federico De Marco, Simon R. Redwood, John C. Lisko, Vasilis C. Babaliaros, Mika Laine, Roberto Nerla, Fausto Castriota, Ariel Finkelstein, Itamar Loewenstein, Amnon Eitan, Ronen Jaffe, Philipp Ruile, Franz J. Neumann, Nicolo Piazza, Hind Alosaimi, Horst Sievert, Kolja Sievert, Marco Russo, Martin Andreas, Matjaz Bunc, Azeem Latib, Rebecca Godfrey, David Hildick-Smith, Ming-Yu A. Chuang, Philipp Blanke, Jonathon Leipsic, David A. Wood, Tamim M. Nazif, Susheel Kodali, Marco Barbanti, Ran Kornowski, Martin B. Leon, John G. Webb
Journal: Journal of the American College of Cardiology (2021)
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
Authors: Michael Kreuter, Joyce S. Lee, Argyrios Tzouvelekis, Justin M. Oldham, Philip L. Molyneaux, Derek Weycker, Mark Atwood, Klaus-Uwe Kirchgaessler, Toby M. Maher
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

Rationale: There is an urgent need for simple, cost-effective prognostic biomarkers for idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count. Objectives: We used pooled data from pirfenidone and IFNγ-1b trials to explore the association between monocyte count and prognosis in patients with IPF. Methods: This retrospective pooled analysis included patients (active and placebo arms) from the following four phase III, randomized, placebo-controlled trials: ASCEND (NCT01366209), CAPACITY (NCT00287729 and NCT00287716), and INSPIRE (NCT00075998). Outcomes included IPF progression (≥10% absolute decline in FVC% predicted, ≥50 m decline in 6-minute-walk distance, or death), all-cause hospitalization, and all-cause mortality over 1 year. The relationship between monocyte count (defined as time-dependent) and outcomes was assessed using bivariate and multivariable models. Measurements and Main Results: This analysis included 2,067 patients stratified by monocyte count (at baseline: <0.60 × 109 cells/L [n = 1,609], 0.60 to <0.95 × 109 cells/L [n = 408], and ≥0.95 × 109 cells/L [n = 50]). In adjusted analyses, a higher proportion of patients with monocyte counts of 0.60 to <0.95 × 109 cells/L or ≥0.95 × 109 cells/L versus <0.60 × 109 cells/L experienced IPF progression (P = 0.016 and P = 0.002, respectively), all-cause hospitalization (P = 0.030 and P = 0.003, respectively), and all-cause mortality (P = 0.005 and P < 0.001, respectively) over 1 year. Change in monocyte count from baseline was not associated with any of the outcomes over 1 year and did not appear to be affected by study treatment. Conclusions: In patients with IPF, elevated monocyte count was associated with increased risks of IPF progression, hospitalization, and mortality. Monocyte count may provide a simple and inexpensive prognostic biomarker in IPF.
One Step Forward and Two Steps Back With Drug-Eluting-Stents: From Preventing Restenosis to Causing Late Thrombosis and Nouveau Atherosclerosis⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.
Authors: Gaku Nakazawa, Marc Vorpahl, Aloke V. Finn, Jagat Narula, Renu Virmani
Journal: JACC. Cardiovascular imaging (2009)
UK recommendations on opioid stewardship
Authors: Nicholas Levy, Linda J Lord, Dileep N Lobo
Journal: BMJ (2021)

The effect of the prescription opioid crisis in North America is well documented. 1 In 2018 some 68 500 Americans died from opioid overdoses, and in 2015 the cost of opioid misuse to the US economy was estimated at $150bn (£110bn; €120bn). 1 The EU now has an estimated 1.3 million high-risk opioid users, 1 and 110 000 people worldwide died from opioid use disorders in 2017-77% more than in 2007. 2Opioids were prescribed to roughly 5% of the UK population in 2015. 3Between 1998 and 2016, opioid prescriptions increased by 34% in England, and the total oral morphine equivalence dose increased by 127% to 431 000 mg/1000 population/year. 4A recent UK study found that 14.6% of people given opioids for the first time became long term opioid users within a year. 5 response to this healthcare crisis, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued recommendations that before prescribing opioids, clinicians must discuss the risks and features of tolerance, dependence, and addiction with patients, and jointly agree a treatment strategy and plan for the end of treatment. 6These new recommendations have the potential to alter opioid prescribing habits substantially.The UK General Medical Council advises that clinicians should comply with MHRA recommendations along with other guidance, making compliance a professional duty. 7propriate prescribing of opioids should be a priority, focusing where possible on nonpharmacological strategies, including referral to wellbeing services, physiotherapy, exercise, and weight loss programmes, as well as alternative therapies such as mind-body therapy and acupuncture.
Natural products in drug discovery: advances and opportunities
Authors: Atanas G. Atanasov, Sergey B. Zotchev, Verena M. Dirsch, Ilkay Erdogan Orhan, Maciej Banach, Judith M. Rollinger, Davide Barreca, Wolfram Weckwerth, Rudolf Bauer, Edward A. Bayer, Muhammed Majeed, Anupam Bishayee, Valery Bochkov, Günther K. Bonn, Nady Braidy, Franz Bucar, Alejandro Cifuentes, Grazia D’Onofrio, Michael Bodkin, Marc Diederich, Albena T. Dinkova-Kostova, Thomas Efferth, Khalid El Bairi, Nicolas Arkells, Tai-Ping Fan, Bernd L. Fiebich, Michael Freissmuth, Milen I. Georgiev, Simon Gibbons, Keith M. Godfrey, Christian W. Gruber, Jag Heer, Lukas A. Huber, Elena Ibanez, Anake Kijjoa, Anna K. Kiss, Aiping Lu, Francisco A. Macias, Mark J. S. Miller, Andrei Mocan, Rolf Müller, Ferdinando Nicoletti, George Perry, Valeria Pittalà, Luca Rastrelli, Michael Ristow, Gian Luigi Russo, Ana Sanches Silva, Daniela Schuster, Helen Sheridan, Krystyna Skalicka-Woźniak, Leandros Skaltsounis, Eduardo Sobarzo-Sánchez, David S. Bredt, Hermann Stuppner, Antoni Sureda, Nikolay T. Tzvetkov, Rosa Anna Vacca, Bharat B. Aggarwal, Maurizio Battino, Francesca Giampieri, Michael Wink, Jean-Luc Wolfender, Jianbo Xiao, Andy Wai Kan Yeung, Gérard Lizard, Michael A. Popp, Michael Heinrich, Ioana Berindan-Neagoe, Marc Stadler, Maria Daglia, Robert Verpoorte, Claudiu T. Supuran
Journal: Nature Reviews Drug Discovery (2021)
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial
Authors: Samuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, Noam F. Ponde, Andrea Gombos, Vicki Paterson, Florentine Hilbers, Larissa Korde, Anna Manukyants, Amylou Dueck, Christian Maurer, Martine Piccart, Alvaro Moreno-Aspitia, Christine Desmedt, Serena Di Cosimo, Evandro de Azambuja
Journal: Journal of the National Comprehensive Cancer Network (2021)

The association between obesity and prognosis in HER2-positive early breast cancer remains unclear, with limited data available. This study aimed to determine the impact of body mass index (BMI) at baseline and weight change after 2 years on outcomes of patients with HER2-positive early breast cancer.ALTTO was a randomized phase III trial in patients with HER2-positive early breast cancer. BMI was collected at randomization and 2 years after. WHO BMI categories were used: underweight, <18.5 kg/m2; normal weight, 18.5 to <25 kg/m2; overweight, ≥25 to <30 kg/m2; and obese ≥30 kg/m2. A weight change from baseline of ≥5.0% and ≤5.0% was categorized as weight gain and weight loss. The impact of BMI at randomization and of weight change on disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS) were investigated with multivariate analyses, adjusting for baseline patients and tumor characteristics.A total of 8,381 patients were included: 187 (2.2%), 3,797 (45.3%), 2,690 (32.1%), and 1,707 (20.4%) were underweight, normal weight, overweight, and obese at baseline, respectively. Compared with normal weight, being obese at randomization was associated with a significantly worse DDFS (adjusted hazard ratio [aHR], 1.25; 95% CI, 1.04-1.50) and OS (aHR, 1.27; 95% CI, 1.01-1.60), but no significant difference in DFS (aHR, 1.14; 95% CI, 0.97-1.32). Weight loss ≥5.0% at 2 years after randomization was associated with significantly poorer DFS (aHR, 1.34; 95% CI, 1.05-1.71), DDFS (aHR, 1.46; 95% CI, 1.07-1.98), and OS (aHR, 1.83; 95% CI, 1.18-2.84). Hormone receptor and menopausal status but not anti-HER2 treatment type influenced outcomes. Toxicities were more frequent in obese patients.In patients with HER2-positive early breast cancer, obesity at baseline is a poor prognostic factor. Weight loss during treatment and follow-up negatively impacts clinical outcomes. Dietary counseling should be part of survivorship care programs.
Are you translating research into clinical practice? What to think about when it does not seem to be working
Authors: Myles Calder Murphy, William Gibson, G Lorimer Moseley, Ebonie Kendra Rio
Journal: British Journal of Sports Medicine (2021)

The value of clinical research can be lost in translation and implementation. One often overlooked issue is whether clinicians can determine if their patient is similar to research participants and, ipso facto, whether the clinician treating that patient will have the same effects as what was reported in a research study. We present five questions and clinical tips for clinicians.

The characteristics of a research study’s participants can be considered their ‘clinical phenotype’. The field dedicated to more precisely matching treatments to clinical phenotypes is ‘precision medicine’.1 Defining clinical phenotypes is a challenge in musculoskeletal research because a gold standard diagnostic test is commonly absent. For example, the single leg decline squat is provocative for anterior knee pain but is not diagnostic for patellar tendinopathy.2 Even where clinicians agree that a patient group has the same condition (eg, rotator cuff tendinopathy), different clinical phenotypes (eg, positive vs negative empty can test) within that group means the population is heterogenous. This may mean that subgroups of patients will respond differently to interventions.

### Clinical tip

Do not rely on the title or abstract of a paper. Review the methods section for details on more precise clinical phenotypes (or not), including how the condition was diagnosed and other features, such as physical activity, education, cognitive or socioeconomic characteristics.3 Does your …
Laparoscopic Liver Resection versus Percutaneous Radiofrequency Ablation for Small Single Nodular Hepatocellular Carcinoma: Comparison of Treatment Outcomes
Authors: Dong Ho Lee, Jing Woong Kim, Jeong Min Lee, Jong Man Kim, Min Woo Lee, Hyunchul Rhim, Young Hoe Hur, Kyung-Suk Suh
Journal: Liver Cancer (2021)

Treatment outcomes of laparoscopic liver resection (LLR) and percutaneous radiofrequency ablation (p-RFA) for small single hepatocellular carcinomas (HCCs) have not yet been fully compared. The aim of this study was to compare LLR and p-RFA as first-line treatment options in patients with single nodular HCCs ≤3 cm.From January 2014 to December 2016, a total of 566 patients with single nodular HCC ≤3 cm treated by either LLR (n = 251) or p-RFA (n = 315) were included. The recurrence-free survival (RFS) and cumulative incidence of local tumor progression (LTP) were estimated using Kaplan-Meier methods and compared using the log-rank test. Treatment outcome of 2 treatment modalities was compared in the subgroup of patients according to the tumor location.There were no significant differences in overall survival between LLR and p-RFA (p = 0.160); however, 3-year RFS was demonstrated to be significantly higher after LLR (74.4%) than after p-RFA (66.0%) (p = 0.013), owing to its significantly lower cumulative incidence of LTP (2.1% at 3 years after LLR vs. 10.0% after p-RFA, p < 0.001). The complication rate of p-RFA was significantly lower than that of LLR (5.1 vs. 10.0%, p = 0.026). LLR also provided significantly better local tumor control than p-RFA for subscapular tumors (3-year LTP rates: 1.9 vs. 8.8%, p = 0.012), perivascular tumors (3-year LTP rates: 0.0 vs. 17.2%, p = 0.007), and tumors located in anteroinfero-lateral liver portions (3-year LTP rates: 0.0 vs. 10.7%, p < 0.001). However, there were no significant differences in LTP rates between LLR and p-RFA for non-subcapsular and non-perivascular tumors (p = 0.482) and for tumors in postero-superior liver portions (p = 0.380).LLR can provide significantly better local tumor control than p-RFA for small single HCCs in subcapsular, perivascular, and anteroinferolateral liver portions and thus may be the preferred treatment option for these tumors.
Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma
Authors: Sharanya Maanasi Kalasekar, Ignacio Garrido‐Laguna, Kimberley Jane Evason
Journal: Hepatology (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society
Authors: Martine Remy-Jardin, Christopher J. Ryerson, Mark L. Schiebler, Ann N.C. Leung, James M. Wild, Marius M. Hoeper, Philip O. Alderson, Lawrence R. Goodman, John Mayo, Linda B. Haramati, Yoshiharu Ohno, Patricia Thistlethwaite, Edwin J.R. van Beek, Shandra Lee Knight, David A. Lynch, Geoffrey D. Rubin, Marc Humbert
Journal: European Respiratory Journal (2021)

Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure greater than 20 mmHg and classified into five different groups sharing similar pathophysiologic mechanisms, haemodynamic characteristics, and therapeutic management. Radiologists play a key role in the multidisciplinary assessment and management of PH. A working group was formed from within the Fleischner Society based on expertise in the imaging and/or management of patients with PH, as well as experience with methodologies of systematic reviews. The working group identified key questions focusing on the utility of CT, MRI, and nuclear medicine in the evaluation of PH: a) Is noninvasive imaging capable of identifying PH? b) What is the role of imaging in establishing the cause of PH? c) How does imaging determine the severity and complications of PH? d) How should imaging be used to assess chronic thromboembolic PH before treatment? e) Should imaging be performed after treatment of PH? This systematic review and position paper highlights the key role of imaging in the recognition, work-up, treatment planning, and follow-up of PH.
Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia
Authors: Yu-Jun Dai, Si-Yuan He, Fang Hu, Xue-Ping Li, Jian-Ming Zhang, Si-Liang Chen, Wei-Na Zhang, Hai-Min Sun, Da-Wei Wang
Journal: Molecular Cancer (2021)

Abstract Acute myeloid leukemia (AML) is still incurable due to its heterogeneity and complexity of tumor microenvironment. It is imperative therefore to understand the molecular pathogenesis of AML and identify leukemia-associated biomarkers to formulate effective treatment strategies. Here, we systematically analyzed the clinical characters and natural killer (NK) cells portion in seventy newly-diagnosis (ND) AML patients. We found that the proportion of NK cells in the bone marrow of ND-AML patients could predict the prognosis of patients by analyzing the types and expression abundance of NK related ligands in tumor cells. Furthermore, MCL1 inhibitor but not BCL2 inhibitor combined with NK cell-based immunotherapy could effectively improve the therapeutic efficiency via inhibiting proliferation and inducing apoptosis of AML primary cells as well as cell lines in vitro. There results provide valuable insights that could help for exploring new therapeutic strategies for leukemia treatment.